{"doi":"10.1093/oncolo/oyad338","title":"First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors","abstract":"PURPOSE: This first-in-human phase I dose-escalation study evaluated the safety, pharmacokinetics, and efficacy of tinengotinib (TT-00420), a multi-kinase inhibitor targeting fibroblast growth factor receptors 1-3 (FGFRs 1-3), Janus kinase 1/2, vascular endothelial growth factor receptors, and Aurora A/B, in patients with advanced solid tumors. PATIENTS AND METHODS: Patients received tinengotinib orally daily in 28-day cycles. Dose escalation was guided by Bayesian modeling using escalation with overdose control. The primary objective was to assess dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and dose recommended for dose expansion (DRDE). Secondary objectives included pharmacokinetics and efficacy. RESULTS: Forty-eight patients were enrolled (dose escalation, n = 40; dose expansion, n = 8). MTD was not reached; DRDE was 12 mg daily. DLTs were palmar-plantar erythrodysesthesia syndrome (8 mg, n = 1) and hypertension (15 mg, n = 2). The most common treatment-related adverse event was hypertension (50.0%). In 43 response-evaluable patients, 13 (30.2%) achieved partial response (PR; n = 7) or stable disease (SD) ≥ 24 weeks (n = 6), including 4/11 (36.4%) with FGFR2 mutations/fusions and cholangiocarcinoma (PR n = 3; SD ≥ 24 weeks n = 1), 3/3 (100.0%) with hormone receptor (HR)-positive/HER2-negative breast cancer (PR n = 2; SD ≥ 24 weeks n = 1), 2/5 (40.0%) with triple-negative breast cancer (TNBC; PR n = 1; SD ≥ 24 weeks n = 1), and 1/1 (100.0%) with castrate-resistant prostate cancer (CRPC; PR). Four of 12 patients (33.3%; HR-positive/HER2-negative breast cancer, TNBC, prostate cancer, and cholangiocarcinoma) treated at DRDE had PRs. Tinengotinib's half-life was 28-34 hours. CONCLUSIONS: Tinengotinib was well tolerated with favorable pharmacokinetic characteristics. Preliminary findings indicated potential clinical benefit in FGFR inhibitor-refractory cholangiocarcinoma, HER2-negative breast cancer (including TNBC), and CRPC. Continued evaluation of tinengotinib is warranted in phase II trials.","journal":"The Oncologist","year":2024,"id":422120,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":27,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8212,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":701718,"name":"Binghe Xu","orcid":"0000-0003-4195-337X","position":1,"is_corresponding":false},{"id":266116,"name":"Ecaterina E. Dumbrava","orcid":"0000-0002-1959-0536","position":2,"is_corresponding":false},{"id":241553,"name":"Siqing Fu","orcid":"0000-0002-1933-0419","position":3,"is_corresponding":false},{"id":266107,"name":"Daniel D. Karp","orcid":"0000-0002-5017-328X","position":4,"is_corresponding":false},{"id":70220,"name":"Funda Meric‐Bernstam","orcid":"0000-0001-6816-6072","position":5,"is_corresponding":false},{"id":107725,"name":"David S. Hong","orcid":"0000-0001-8721-1609","position":6,"is_corresponding":false},{"id":259631,"name":"Jordi Rodón","orcid":"0000-0001-6467-3632","position":7,"is_corresponding":false},{"id":108756,"name":"Apostolia M. Tsimberidou","orcid":"0000-0003-2713-233X","position":8,"is_corresponding":false},{"id":264370,"name":"Kanwal Raghav","orcid":"0000-0003-1311-4173","position":9,"is_corresponding":false},{"id":69924,"name":"Jaffer A. Ajani","orcid":"0000-0001-9946-0629","position":10,"is_corresponding":false},{"id":740937,"name":"Anthony P. Conley","orcid":"0000-0002-6232-1163","position":11,"is_corresponding":false},{"id":247611,"name":"Frank E. Mott","orcid":"0000-0003-2963-5328","position":12,"is_corresponding":false},{"id":1215755,"name":"Ying Fan","orcid":"0000-0001-7638-2488","position":13,"is_corresponding":false},{"id":25158,"name":"Jean Fan","orcid":"0000-0002-0212-5451","position":14,"is_corresponding":false},{"id":1215756,"name":"Peng Peng","orcid":"0000-0002-8341-3008","position":15,"is_corresponding":false},{"id":437421,"name":"Hui Wang","orcid":"0000-0001-8478-9990","position":16,"is_corresponding":false},{"id":1215757,"name":"Shumao Ni","orcid":"0000-0001-6891-2936","position":17,"is_corresponding":false},{"id":1211969,"name":"Caixia Sun","orcid":"0000-0001-8169-2464","position":18,"is_corresponding":false},{"id":1216422,"name":"Xiaoyan Qiang","orcid":null,"position":19,"is_corresponding":false},{"id":42003,"name":"Wendy J. Levin","orcid":null,"position":20,"is_corresponding":false},{"id":783287,"name":"Brenda Ngo","orcid":null,"position":21,"is_corresponding":false},{"id":1216423,"name":"Qinhua Ru","orcid":null,"position":22,"is_corresponding":false},{"id":1211972,"name":"Frank Wu","orcid":"0000-0001-9927-739X","position":23,"is_corresponding":false},{"id":226645,"name":"Milind Javle","orcid":"0000-0001-9158-0941","position":24,"is_corresponding":false},{"id":258839,"name":"Sarina A. Piha‐Paul","orcid":"0000-0001-9455-1660","position":0,"is_corresponding":true}],"reference_count":52,"raw_metadata":null,"created_at":"2026-07-19T01:57:46.393290Z","pmid":"38297981","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}